Nepafenac

CAS 78281-72-8 7 current recordsSmall Molecule

Who holds supplier records for Nepafenac? 7 organisations hold a current record for Nepafenac: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: India (2), France (1), Switzerland (1) and Spain (1); not recorded for 2.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Nepafenac: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/nepafenac

Reading the evidence

  • 7 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 3 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Nepafenac expires 31 Mar 2032. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (7)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Nepafenac. Country is the organisation's recorded country, not necessarily the manufacturing site.

India2France1Switzerland1Spain1Country not recorded for 2
  • CHEMWERTH INC
    Active DMF 28205, 25528 · latest filing Dec 2015
    France
  • MATRIX PHARMACORP PRIVATE LTD
    Active DMF 30593, 30594 · latest filing Jun 2016
    India
  • ALP PHARM BEIJING CO LTD
    Active DMF 23032 · latest filing Jul 2009
  • Carbogen Amcis AG
    Active DMF 17812 · latest filing Nov 2004
    Switzerland Company GMP cert on record
  • FDC Limited
    Active DMF 40618 · latest filing Oct 2024
    India Company GMP cert on record
  • MEDICHEM SA
    Active DMF 28432 · latest filing Jul 2014
    Spain Company GMP cert on record
  • SIEGFRIED GRAFTON INC
    Active DMF 22636 · latest filing Mar 2009
Need Nepafenac sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (2 listed products contain Nepafenac). The latest listed patent expires 31 Mar 2032. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Nepafenac is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL1021).

Chemical identity

IUPAC name
2-(2-amino-3-benzoylphenyl)acetamide
Canonical SMILES
C1=CC=C(C=C1)C(=O)C2=CC=CC(=C2N)CC(=O)N
InChIKey
QEFAQIPZVLVERP-UHFFFAOYSA-N
Synonyms
AHR-9434, AL-6515, Ilevro, Nepafenac, Nepafenaco, Nevanac, 2-(2-Amino-3-benzoylphenyl)acetamide, 2-Amino-3-benzoylbenzeneacetamide, AL 6515, nepafenacum, CHEBI:75922, Nepafenac [USAN:INN:BAN:JAN]

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Nonsteroidal Anti-inflammatory Drug
Mechanism of action
Cyclooxygenase Inhibitors
Chemical structure
Non-Steroidal

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Nepafenac?

7 organisations hold an active US FDA Type II Drug Master File or a CEP for Nepafenac: CHEMWERTH INC (France), MATRIX PHARMACORP PRIVATE LTD (India), ALP PHARM BEIJING CO LTD, Carbogen Amcis AG (Switzerland), FDC Limited (India), MEDICHEM SA (Spain) and SIEGFRIED GRAFTON INC. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Nepafenac Drug Master Files are active?

CHEMWERTH INC (DMF 28205, 25528), MATRIX PHARMACORP PRIVATE LTD (DMF 30593, 30594), ALP PHARM BEIJING CO LTD (DMF 23032), Carbogen Amcis AG (DMF 17812), FDC Limited (DMF 40618), MEDICHEM SA (DMF 28432) and SIEGFRIED GRAFTON INC (DMF 22636). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

Does the FDA Orange Book list patents for products containing Nepafenac?

Yes. The latest patent listed for an approved US product containing Nepafenac expires 31 Mar 2032, across 2 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Nepafenac supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Nepafenac?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.